Longitudinal Study for the Characterization of the Phases of Subjective Perception of Cognitive Decline and Mild Cognitive Impairment of Alzheimer's Disease.

Launched by BARCELONABETA BRAIN RESEARCH CENTER, PASQUAL MARAGALL FOUNDATION · Feb 21, 2019

Keywords

ClinConnect Summary

This clinical trial is studying how people perceive their own memory and thinking abilities as they age, particularly in relation to Alzheimer's disease (AD) and mild cognitive impairment (MCI). Researchers want to understand the different stages of cognitive decline, starting from when individuals first notice subtle changes in their thinking (called subjective cognitive decline or SCD) to more advanced stages of dementia. By examining these stages, the researchers hope to identify who might be at risk for developing more serious cognitive issues and when it might be best to intervene with preventive treatments.

To participate in this study, individuals must be between 45 and 74 years old and either be cognitively healthy but experiencing SCD, or have MCI or mild dementia. It's important that a family member or close friend also participates, as they will help provide insights into the participant's memory complaints during interviews. Participants can expect to undergo cognitive tests and possibly provide biological samples to help researchers track changes in memory and thinking over time. This study aims to gather valuable information that could lead to earlier detection and better prevention strategies for Alzheimer's disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Men and women between 45 and 74 years at the time of inclusion in the 45-65/FPM2012 study or older than 45 for persons who have not previously participated in 45-65/FPM2012.
• • 2. Cognitively healthy persons with SCD, as well as people with MCI and mild dementia.
• • 3. Participation of a relative to perform the subjective memory complaint and clinical interview.
• Exclusion criteria:
• • 1. Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol.
• • 2. Any significant disorder that could course with cognitive impairment that is not related to AD.
• • 3. Family history of monogenic AD.